Bone Therapeutics Raises $10.4M To Speed Phase III Cell Therapy Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgium's Bone Therapeutics raises $10.4 million in a Series D financing to fund a Phase III study of its lead product, an osteoblast cell therapy for osteonecrosis of the hip and non-union bone fractures.